Drugs / Brequinar
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04425252 | Aug → Dec 2020 | COVID-19 | Clear Creek Bio, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03760666 | Dec 2018 → Dec 2020 | acute myeloid leukemia | Clear Creek Bio, Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05166876 | Feb → Jun 2022 | COVID-19 | Clear Creek Bio, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04575038 | Nov 2020 → Apr 2021 | COVID-19 | Clear Creek Bio, Inc. | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-02-14 | Clear Creek Bio, Inc. | Fierce Pharma COVID-19 Tracker Covers Brequinar as a Potential Antiviral COVID-19 Oral Treatment clearcreekbio.com ↗ |
| 2020-11-20 | Clear Creek Bio, Inc. | Clear Creek Bio Doses First Patient in Phase 2 Outpatient Study of Brequinar to Treat COVID-19 clearcreekbio.com ↗ |
| 2020-09-01 | Clear Creek Bio, Inc. | Clear Creek Bio Doses First Patient in Clinical Study of Brequinar in Hospitalized COVID-19 Patients clearcreekbio.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brequinar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04425252 ↗ |
| Known as | Brequinar Sodium | “Drug: Brequinar Sodium” NCT05166876 ↗ |
| Known as | Brequinar sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL38434 ↗ |
| Known as | DUP 785 | ChEMBL registry synonym — accepted as the source's own label CHEMBL38434 ↗ |
| Known as | NSC-368390 | ChEMBL registry synonym — accepted as the source's own label CHEMBL38434 ↗ |
| Action | Inhibit | “DHODH inhibitor, 100 mg daily x 5 days” NCT04425252 ↗ |
| Modality | Small molecule | — CHEMBL38434 ↗ |
| Route | Oral | “Brequinar and ribavirin were dosed orally” NCT03760666 ↗ |
| Target | DHODH | “DHODH inhibitor, 100 mg daily x 5 days” NCT04425252 ↗ |